Gene Signal Novel Corneal Neovascularization Product Still On Track Despite Primary Endpoint Miss
This article was originally published in The Pink Sheet Daily
Executive Summary
Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.